{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T03:29:25Z","timestamp":1763177365625,"version":"3.45.0"},"reference-count":39,"publisher":"Japanese Circulation Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2025,11,10]]},"DOI":"10.1253\/circrep.cr-25-0138","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T22:06:44Z","timestamp":1757023604000},"page":"1029-1036","source":"Crossref","is-referenced-by-count":0,"title":["Preventive Effect of Nifekalant on Recurrent Ventricular Fibrillation and Electrical Storm\u3000\u2015 A Systematic Review and Meta-Analysis \u2015"],"prefix":"10.1253","volume":"7","author":[{"given":"Kazuo","family":"Sakamoto","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyushu University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Iijima","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Biology and Medicine, Juntendo University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuma","family":"Kawaji","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Mitsubishi Kyoto Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Kitai","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Sapporo Cardiovascular Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Hosaka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Niigata City General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutsuko","family":"Sangawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Takamatsu Red Cross Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Shiomi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masashi","family":"Yokose","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Generalist Medicine, Dokkyo Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Hiraoka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Tokyo Bay Urayasu Ichikawa Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Steel Memorial Muroran Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Matoba","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyushu University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Migaku","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Emergency and Critical Care Center, Dokkyo Medical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Tahara","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nonogi","sequence":"additional","affiliation":[{"name":"Pharmaceutical Science, University of Shizuoka"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruo","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Tsujimoto","sequence":"additional","affiliation":[{"name":"Systematic Review Workshop Peer Support Group (SRWS-PSG)"},{"name":"Oku Medical Clinic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshikazu","family":"Funazaki","sequence":"additional","affiliation":[{"name":"Kawaguchi Cupola Rehabilitation Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the Japan Resuscitation Council (JRC) Emergency Cardiovascular Care (ECC) Arrhythmia Task Force and the Guideline Editorial Committee on behalf of the Japanese Circulation Society (JCS) Emergency and Critical Care Committee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. <i>Eur Heart J<\/i> 2022; 43: 3997\u20134126.","DOI":"10.1093\/eurheartj\/ehac699"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ono K, Iwasaki YK, Akao M, Ikeda T, Ishii K, Inden Y, et al. JCS\/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias. <i>Circ J<\/i> 2022; 86: 1790\u20131924.","DOI":"10.1253\/circj.CJ-22-0285"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Yasuda S, Sawano H, Hazui H, Ukai I, Yokoyama H, Ohashi J, et al. Report from J-PULSE multicenter registry of patients with shock-resistant out-of-hospital cardiac arrest treated with nifekalant hydrochloride. <i>Circ J<\/i> 2010; 74: 2308\u20132313.","DOI":"10.1253\/circj.CJ-09-0759"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Tahara Y, Kimura K, Kosuge M, Ebina T, Sumita S, Hibi K, et al. Comparison of nifekalant and lidocaine for the treatment of shock-refractory ventricular fibrillation. <i>Circ J<\/i> 2006; 70: 442\u2013446.","DOI":"10.1253\/circj.70.442"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Watanabe H, Chinushi M, Washizuka T, Sugiura H, Hirono T, Aizawa Y, et al. Comparison of efficacy of sotalol and nifekalant for ventricular tachyarrhythmias. <i>Circ J<\/i> 2006; 70: 583\u2013587.","DOI":"10.1253\/circj.70.583"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Shiga T, Shiozaki M, Takahashi R, Matsumoto R, Fukui M. Post-marketing surveillance of the safety of landiolol in patients with recurrent hemodynamically unstable ventricular tachyarrhythmias. <i>Circ J<\/i> 2025; 89: 784\u2013792.","DOI":"10.1253\/circj.CJ-24-0898"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Panchal AR, Bartos JA, Caba\u00f1as JG, Donnino MW, Drennan IR, Hirsch KG, et al. Part 3: Adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. <i>Circulation<\/i> 2020; 142: S366\u2013S468.","DOI":"10.1161\/CIR.0000000000000918"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Katoh T, Mitamura H, Matsuda N, Takano T, Ogawa S, Kasanuki H. Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias: Post-marketing special investigation. <i>Circ J<\/i> 2005; 69: 1237\u20131243.","DOI":"10.1253\/circj.69.1237"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kodama I, Kamiya K, Toyama J. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. <i>Am J Cardiol<\/i> 1999; 84: 20R\u201328R.","DOI":"10.1016\/S0002-9149(99)00698-0"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Cheng J, Kamiya K, Kodama I, Toyama J. Differential effects of MS-551 and E-4031 on action potentials and the delayed rectifier K<sup>+<\/sup> current in rabbit ventricular myocytes. <i>Cardiovasc Res<\/i> 1996; 31: 963\u2013974.","DOI":"10.1016\/S0008-6363(96)00049-1"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Amino M, Inokuchi S, Nagao K, Nakagawa Y, Yoshioka K, Ikari Y, et al. Nifekalant hydrochloride and amiodarone hydrochloride result in similar improvements for 24-hour survival in cardiopulmonary arrest patients: The SOS-KANTO 2012 Study Study. <i>J Cardiovasc Pharmacol<\/i> 2015; 66: 600\u2013609.","DOI":"10.1097\/FJC.0000000000000310"},{"key":"12","unstructured":"12. Funakoshi H, Aso S, Homma Y, Onodera R, Tahara Y. Nifekalant versus amiodarone for out-of-hospital cardiac arrest with refractory shockable rhythms: A post hoc analysis. <i>Arch Acad Emerg Med<\/i> 2022; 10: e6."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Harayama N, Nihei S, Nagata K, Isa Y, Goto K, Aibara K, et al. Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation. <i>J Anesth<\/i> 2014; 28: 587\u2013592.","DOI":"10.1007\/s00540-013-1775-5"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. <i>BMJ<\/i> 2021; 372: n160.","DOI":"10.1136\/bmj.n160"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Liberati A, Altman DG, Tetzlaff J, Mulrow C, G\u00f8tzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. <i>J Clin Epidemiol<\/i> 2009; 62: e1\u2013e34.","DOI":"10.1016\/j.jclinepi.2009.06.006"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, et al. Robins-I: A tool for assessing risk of bias in non-randomised studies of interventions. <i>BMJ<\/i> 2016; 355: i4919.","DOI":"10.1136\/bmj.i4919"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Huedo-Medina TB, S\u00e1nchez-Meca J, Mar\u00edn-Mart\u00ednez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? <i>Psychol Methods<\/i> 2006; 11: 193\u2013206.","DOI":"10.1037\/1082-989X.11.2.193"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Atkins D, Eccles M, Flottorp S, Guyatt GH, Henry D, Hill S, et al. Systems for grading the quality of evidence and the strength of recommendations I: Critical appraisal of existing approaches The GRADE Working Group. <i>BMC Health Serv Res<\/i> 2004; 4: 38.","DOI":"10.1186\/1472-6963-4-38"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Mustafa RA, Santesso N, Brozek J, Akl EA, Walter SD, Norman G, et al. The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses. <i>J Clin Epidemiol<\/i> 2013; 66: 736\u2013742.","DOI":"10.1016\/j.jclinepi.2013.02.004"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Guyatt GH, Oxman AD, Sch\u00fcnemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: A new series of articles in the <i>Journal of Clinical Epidemiology<\/i>. <i>J Clin Epidemiol<\/i> 2011; 64: 380\u2013382.","DOI":"10.1016\/j.jclinepi.2010.09.011"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. <i>BMJ<\/i> 2021; 372: n71.","DOI":"10.1136\/bmj.n71"},{"key":"22","unstructured":"22. Yamazaki K, Takahashi H, Tsuda Y, Inohara M, Nuruki Y, Kudou M, et al. The effects of nifekalant and amiodarone on lethal ventricular arrhythmia. <i>Shinzo<\/i> 2010; 42: 117\u2013122."},{"key":"23","unstructured":"23. Miyauchi M. The role of amiodarone in electrical storm. <i>Prog Med<\/i> 2010; 30: 747\u2013752."},{"key":"24","unstructured":"24. Mera N, Yusu S, Hoshida K, Yanagisawa R, Miyagoshi M, Miwa R, et al. Treatment outcomes of Class III antiarrhythmic drugs for electrical storm in our own cases: Nifecarane vs. amiodarone. <i>Prog Med<\/i> 2012; 32: 420\u2013423."},{"key":"25","unstructured":"25. Sasaki K, Sasaki S, Kimura M, Owada S, Horiuchi D, Itou T, et al. Investigations about the ECG changes and efficacy in preventing recurrences of fatal ventricular arrhythmia using amiodarone or nifekalant. <i>Prog Med<\/i> 2010; 30: 726\u2013729."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Suzuki M, Nagahori W, Mizukami A, Matsumura A, Hashimoto Y. A multicenter observational study of the effectiveness of antiarrhythmic agents in ventricular arrhythmias: A propensity-score adjusted analysis. <i>J Arrhythm<\/i> 2016; 32: 186\u2013190.","DOI":"10.1016\/j.joa.2016.01.004"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Sato S, Zamami Y, Imai T, Tanaka S, Koyama T, Niimura T, et al. Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia. <i>Sci Rep<\/i> 2017; 7: 12683.","DOI":"10.1038\/s41598-017-13073-0"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Amino M, Yoshioka K, Opthof T, Morita S, Uemura S, Tamura K, et al. Comparative study of nifekalant versus amiodarone for shock-resistant ventricular fibrillation in out-of-hospital cardiopulmonary arrest patients. <i>J Cardiovasc Pharmacol<\/i> 2010; 55: 391\u2013398.","DOI":"10.1097\/FJC.0b013e3181d3dcc7"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Amino M, Yoshioka K, Kanda S, Deguchi Y, Nakamura M, Kobayashi Y, et al. Systematic review of the use of intravenous amiodarone and nifekalant for cardiopulmonary resuscitation in Japan. <i>J Arrhythm<\/i> 2014; 30: 180\u2013185.","DOI":"10.1016\/j.joa.2013.10.001"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Gelman I, Sharma N, McKeeman O, Lee P, Campagna N, Tomei N, et al. The ion channel basis of pharmacological effects of amiodarone on myocardial electrophysiological properties, a comprehensive review. <i>Biomed Pharmacother<\/i> 2024; 174: 116513.","DOI":"10.1016\/j.biopha.2024.116513"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Katoh T, Ogawa S, Kasanuki H. QT prolongation and torsades de pointes during emergency treatment with nifekalant for refractory ventricular tachyarrhythmias: Post-hoc analysis from a large-scale multicenter post-marketing survey in Japan. <i>J Arrhythm<\/i> 2013; 29: 249\u2013254.","DOI":"10.1016\/j.joa.2012.12.013"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Monoe C, Shimizu H, Kitaguchi K, Funakoshi H. Severe bradycardia induced by sofosbuvir and amiodarone which resolved after the discontinuation of both drugs. <i>Intern Med<\/i> 2020; 59: 2619\u20132622.","DOI":"10.2169\/internalmedicine.4488-20"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Chowdhury A, Fernandes B, Melhuish TM, White LD. Antiarrhythmics in cardiac arrest: A systematic review and meta-analysis. <i>Heart Lung Circ<\/i> 2018; 27: 280\u2013290.","DOI":"10.1016\/j.hlc.2017.07.004"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Horie M, Saiki H, Aizawa T, Kato K, Fukuyama M, Makiyama T, et al. Congenital short QT syndrome: Review focused on KCNQ1 p.Val141Met variant. <i>Circ J<\/i> 2025, doi:10.1253\/circj.CJ-24-0927.","DOI":"10.1253\/circj.CJ-24-0927"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Kondo Y, Noda T, Takanashi Y, Sasaki S, Satao Y, Nitta T, et al. Two-year outcomes of primary prophylactic use of defibrillators for ischemic and non-ischemic cardiomyopathy: Propensity score-matched analysis from the NiProtocol Paperon Storm Study. <i>Circ J<\/i> 2024; 88: 1107\u20131114.","DOI":"10.1253\/circj.CJ-23-0613"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Yasuoka R, Maruyama M, Nakazawa G, Noda T, Nitta T, Aizawa Y, et al. How electrical storms recur over time in patients with implantable cardioverter defibrillators: Subanalysis of the NiProtocol Paperon Storm Study. <i>Circ J<\/i> 2025; 89: 214\u2013223.","DOI":"10.1253\/circj.CJ-24-0390"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Hanada K, Kinjo T, Yokoyama H, Tsushima M, Senoo M, Ichikawa H, et al. Incidence, predictors, and outcome associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. <i>Circ J<\/i> 2024; 88: 1254\u20131264.","DOI":"10.1253\/circj.CJ-23-0023"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Yusu S, Ikeda T, Mera H, Miyakoshi M, Miwa Y, Abe A, et al. Effects of intravenous nifekalant as a lifesaving drug for severe ventricular tachyarrhythmias complicating acute coronary syndrome. <i>Circ J<\/i> 2009; 73: 2021\u20132028.","DOI":"10.1253\/circj.CJ-09-0375"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Saito Y, Tateishi K, Kobayashi Y. Clinical review of cardiogenic shock after acute myocardial infarction: Revascularization, mechanical circulatory support, and beyond. <i>Circ Rep<\/i> 2025; 7: 6\u201314.","DOI":"10.1253\/circrep.CR-24-0141"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/11\/7_CR-25-0138\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T03:24:33Z","timestamp":1763177073000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/11\/7_CR-25-0138\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-25-0138","relation":{},"ISSN":["2434-0790"],"issn-type":[{"type":"electronic","value":"2434-0790"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"article-number":"CR-25-0138"}}